4 recruiting, 1 active not recruiting. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 4, Active not recruiting 1 |
| Phase 2 | 5 | Recruiting 4, Active not recruiting 1 |
Follow Solid Tumors, Adult: new trials by email Literature Review of Solid Tumors, Adult trials Research Report on Solid Tumors, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor HMPL-A580 - Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Hutchmed | 186 | 2026-03-04 | 2026-09-18 |
| A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg - Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Abbisko Therapeutics Co, Ltd | 401 | 2026-03-02 | 2026-03-11 |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors HMPL-A251 - Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Hutchmed | 147 | 2025-12-16 | 2026-09-22 |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors TNG260, Pembrolizumab - Non Small Cell Lung Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Active not recruiting | Tango Therapeutics, Inc. | 126 | 2023-06-12 | 2026-07-06 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
Adenocarcinoma of Lung (1) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genetic Diseases, Inborn (1)
Anastrozole (1) · Drugs, Investigational (1) · Fulvestrant (1) · Imlunestrant (1) · Letrozole (1) · Metformin (1) · STX-478 (1) · Tamoxifen (1) · abemaciclib (1) · exemestane (1) · palbociclib (1) · pembrolizumab (1) · ribociclib (1)
Hutchmed (2) · Abbisko Therapeutics Co, Ltd (1) · Eli Lilly and Company (1) · Tango Therapeutics, Inc. (1)
United States (4) · China (3) · Belgium (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1)
Adam Crystal, MD, PhD (1) · Xianjun Yu, Doctor (1)
2023 (1)